Divalproex Sodium
Product Images NDC 69189-0046

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 69189-0046). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Ec 125 mg Tablet Label (6918900461)

Packaging label for Divalproex EC (Pink) 125 mg tablet. The label shows manufacturer Citron, lot numbers, and expiration date of 07/21/2016. It includes the NDC 69189-0046 and labeler as Avera McKennan Hospital in Sioux Falls, SD. The label appears on a small pouch or packet.*

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar graph comparing the percentage response rates between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) across two studies, labeled Study 1 (YMRS) and Study 2 (MRS). The graph shows higher percentages for DVPX (60% and 58%) compared to placebo (26% and 29%).*

FDA Label Image

Figure 2 (Divalproex Fig2)

A cumulative response curve chart comparing percent reduction in clinical parameter scores (CPS) rate between Divalproex Sodium Delayed-Release Tablets and placebo across a range of patient percentages. Improvement is indicated upward and worsening downward on the vertical axis, with patient percentage on the horizontal axis.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A chart labeled Figure 3 showing a graph comparing % Reduction in CRS Rate against % of Patients for High Dose and Low Dose groups of Divalproex Sodium. The vertical axis indicates improvement or worsening, with lines representing outcomes for high and low doses.*

FDA Label Image

Figure 4 (Divalproex Fig4)

Bar chart titled 'Mean 4-week Migraine Rates' comparing migraine rates for placebo and Divalproex Sodium Delayed-Release Tablets in two separate studies. The chart shows lower migraine rates for Divalproex Sodium compared to placebo in both studies. Footnotes indicate doses of divalproex sodium delayed-release tablets used in the studies.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of divalproex sodium showing its molecular components and arrangement, including carbon chains, sodium ion, hydroxyl group, and carboxylate groups in a repeated unit polymer format.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.